James Mosedale

Vascular Endothelial Growth Factor (VEGF) is a primary driver of tumor angiogenesis. However, its role extends far beyond simply building new blood vessels to feed a growing tumor. VEGF is a potent immunosuppressor within the tumor microenvironment (TME), actively hindering dendritic...

Introduction

Dietary fiber has long been heralded as a health-promoting nutrient, with recent studies suggesting it may enhance the efficacy of immune checkpoint blockade (ICB) therapies by modulating the gut microbiome. However...

The therapeutic monoclonal antibody landscape has expanded dramatically over the past decades, driven by our deepening understanding of immunoglobulin biology and advances in protein...

Antibody engineering has revolutionized the development of therapeutic antibodies by introducing mutations that modulate various aspects of antibody function. This overview provides a concise summary of key mutation strategies in antibody engineering, including their benefits and challenges.

 ...

The field of cancer immunotherapy has witnessed remarkable advancements in recent years, with immune checkpoint inhibitors (ICIs) at the forefront of this revolution. However, as the limitations of ICIs become...

Introduction

The latest study about the role of autoantigen-specific CD4+ T cell phenotypes in several autoimmune diseases opens a new...

Introduction

A recent revolutionary study in the journal ACS Nano presents a novel immunotherapy approach to treating haematological...

1. Understanding CD8+ T Cell Depletion

The fall or removal of CD8+ T cells, a form of T cell depletion, leads to the recognition and eradicating of various abnormal cells, virally infected cells, and tumor cells because CD8+ T cells are essential components of the immune defense system [1]. There are several ways to eliminate T cells, but antibody-based depletion has become a breakthrough in the respective...

Introduction...